Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents S Gurrapu, SK Jonnalagadda, MA Alam, CT Ronayne, GL Nelson, ... Bioorganic & medicinal chemistry letters 26 (14), 3282-3286, 2016 | 44 | 2016 |
Novel N, N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors S Jonnalagadda, SK Jonnalagadda, CT Ronayne, GL Nelson, LN Solano, ... Oncotarget 10 (24), 2355, 2019 | 35 | 2019 |
Development of novel silyl cyanocinnamic acid derivatives as metabolic plasticity inhibitors for cancer treatment GL Nelson, CT Ronayne, LN Solano, SK Jonnalagadda, S Jonnalagadda, ... Scientific reports 9 (1), 18266, 2019 | 19 | 2019 |
Synthesis and biological evaluation of 2-alkoxycarbonylallyl esters as potential anticancer agents CT Ronayne, LN Solano, GL Nelson, EA Lueth, SL Hubbard, ... Bioorganic & Medicinal Chemistry Letters 27 (4), 776-780, 2017 | 19 | 2017 |
Synthesis, in vitro, and in vivo evaluation of novel N-phenylindazolyl diarylureas as potential anti-cancer agents LN Solano, GL Nelson, CT Ronayne, S Jonnalagadda, SK Jonnalagadda, ... Scientific reports 10 (1), 17969, 2020 | 18 | 2020 |
Synthesis, in vitro, and in vivo evaluation of novel functionalized quaternary ammonium curcuminoids as potential anti-cancer agents LN Solano, GL Nelson, CT Ronayne, EA Lueth, MA Foxley, ... Bioorganic & medicinal chemistry letters 25 (24), 5777-5780, 2015 | 15 | 2015 |
Synthesis and biological evaluation of arylphosphonium-benzoxaborole conjugates as novel anticancer agents SK Jonnalagadda, K Wielenberg, CT Ronayne, S Jonnalagadda, P Kiprof, ... Bioorganic & Medicinal Chemistry Letters 30 (14), 127259, 2020 | 11 | 2020 |
Synthesis and biological evaluation of N, N-dialkylcarboxy coumarin-NO donor conjugates as potential anticancer agents GL Nelson, CT Ronayne, LN Solano, SK Jonnalagadda, S Jonnalagadda, ... Bioorganic & Medicinal Chemistry Letters 52, 128411, 2021 | 10 | 2021 |
Repurposing antimalarial drug mefloquine for cancer Treatment G Mereddy, CJ Ronayne Transl Med (Sunnyvale) 8 (199), 2161-1025.1000199, 2018 | 10 | 2018 |
Synthesis and biological evaluation of novel 2-alkoxycarbonylallylester phosphonium derivatives as potential anticancer agents ZS Gardner, TJ Schumacher, CT Ronayne, GP Kumpati, MJ Williams, ... Bioorganic & Medicinal Chemistry Letters 45, 128136, 2021 | 7 | 2021 |
Targeting adaptive cellular responses to mitochondrial bioenergetic deficiencies in human disease CF Bennett, CT Ronayne, P Puigserver The FEBS journal 289 (22), 6969-6993, 2022 | 5 | 2022 |
Tetracyclines activate mitoribosome quality control and reduce ER stress to promote cell survival CT Ronayne, TD Jackson, CF Bennett, EA Perry, N Kantorovic, ... EMBO reports 24 (12), e57228, 2023 | 3 | 2023 |
Navigating the landscape of mitochondrial-ER communication in health and disease CT Ronayne, P Latorre-Muro Frontiers in Molecular Biosciences 11, 1356500, 2024 | 2 | 2024 |
Tetracycline-dependent inhibition of mitoribosome protein elongation in mitochondrial disease mutant cells suppresses IRE1α to promote cell survival CT Ronayne, CF Bennett, EA Perry, N Kantorovic, P Puigserver bioRxiv, 2023.03. 09.531795, 2023 | 1 | 2023 |
Synthesis and biological evaluation of a novel anticancer agent CBISC that induces DNA damage response and diminishes levels of mutant-p53 CT Ronayne, SK Jonnalagadda, S Jonnalagadda, GL Nelson, LN Solano, ... Biochemical and Biophysical Research Communications 562, 127-132, 2021 | 1 | 2021 |
Biosynthetic and Energetic Lethality of Targeting Metabolic Plasticity for Cancer Treatment CT Ronayne University of Minnesota, 2020 | 1 | 2020 |
Exploring the impact of mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 on breast cancer cell metabolism TJ Schumacher, AV Iyer, J Rumbley, CT Ronayne, VR Mereddy BMC cancer 24, 1415, 2024 | | 2024 |
Development of fluoro-7-aminocarboxycoumarin-based mitochondrial pyruvate carrier inhibitors as anticancer agents TJ Shumacher, ZS Gardner, J Rumbley, CT Ronayne, VR Mereddy bioRxiv, 2024.05. 22.595353, 2024 | | 2024 |
Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy TJ Schumacher, AV Iyer, J Rumbley, CT Ronayne, VR Mereddy bioRxiv, 2024.05. 02.592272, 2024 | | 2024 |
Non-Cancer Drugs for Cancer Treatment (2019-10-31) C Ronayne | | 2019 |